Albumin human
- Generic Name
- Albumin human
- Brand Names
- Albuked, Albuminex, Alburex, Alburx, Albutein, Flexbumin, Hizentra, Human Albumin Grifols, Kedbumin, Octalbin, Plasbumin, Plasmanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9048-46-8
- Unique Ingredient Identifier
- ZIF514RVZR
- Background
Human serum albumin is the primary protein present in human blood plasma. The main function of albumin is to maintain the oncotic pressure of blood . It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). Albumin represents approximately 50% of the total protein co...
- Indication
Albuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass .
- Associated Conditions
- Acute Pyelonephritis(APN), Burns, Hemolytic Disease of the Newborn, Hypoalbuminemia, Hypoproteinemia, Hypovolaemia, Shock, Hypovolemic, Acute fulminant liver failure, Central volume depletion, Post-operative albumin loss
- Associated Therapies
- -
Shilpa Medicare gets nod to conduct Phase III clinical trials for Recombinant Human Albumin 20%
Shilpa Medicare received approval for Phase III clinical trials of Recombinant Human Albumin 20% (rHA), derived from yeast, as a replacement for human serum albumin. Additionally, Shilpa Pharma Lifesciences, a subsidiary, secured a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for Nifedipine, used in hypertension treatment.
The relationship between serum HDL-cholesterol, cardiovascular disease and mortality in ...
Studies show HDL cholesterol's complex relationship with mortality, indicating both protective and paradoxically high-risk associations, particularly in diabetes and cardiovascular disease contexts.
Sonnet BioTherapeutics to Receive Non-Dilutive Funding
Sonnet BioTherapeutics received preliminary approval for a tax credit from NJEDA's Technology Business Tax Certificate Transfer Program, allowing the sale of up to $8.1 million in NOLs and $62,810 in R&D tax credits for $0.795 million. Additionally, Sonnet expects a $0.7 million net cash refund from Australia's R&D Tax Incentive Program, aiding in advancing its immunotherapeutic drug pipeline.
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
Sonnet BioTherapeutics launches CEO Corner platform to provide in-depth perspective on press releases, events, corporate updates, and pipeline progress, aiming to keep shareholders informed and grow value.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath